Ahmed Heshmat, MD
Addiction Medicine · Rockville, MDNPI 1356362263
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 151 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $758, 2.1 times the $355 reported in 2019. Among addiction medicine clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 151 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$489
- Novo Nordisk$365
- Abbott$313
- Amgen$286
- AbbVie$236
- AstraZeneca$99
- plus $1K from 32 others
What the payments were for
- Food & beverage$3,125100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 25 | $489 |
| Novo Nordisk | 20 | $365 |
| Abbott | 10 | $313 |
| Amgen(2 entities) | 10 | $286 |
| AbbVie(2 entities) | 14 | $236 |
| AstraZeneca | 5 | $99 |
| MDD US Operations, LLC | 6 | $94 |
| Astellas Pharma US Inc | 4 | $92 |
| USWM, LLC | 2 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $67 |
| Pfizer | 4 | $63 |
| Tactile Systems Technology Inc | 1 | $57 |
| Orexo US, Inc. | 3 | $55 |
| GSK | 3 | $55 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $54 |
| Alkermes, Inc. | 3 | $54 |
| Exact Sciences | 3 | $52 |
| Inspire Medical Systems, Inc. | 1 | $50 |
| Indivior Inc. | 2 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $45 |
| Ultragenyx Pharmaceutical Inc. | 2 | $45 |
| Gilead | 2 | $44 |
| Novartis | 3 | $44 |
| Eisai Inc. | 2 | $34 |
| Kerecis Limited | 2 | $33 |
| Currax Pharmaceuticals LLC | 2 | $33 |
| Supernus Pharmaceuticals, Inc. | 2 | $30 |
| Jazz Pharmaceuticals Inc. | 2 | $29 |
| Nevro Corp. | 1 | $26 |
| Antares Pharma, Inc. | 1 | $24 |
| Braeburn Inc. | 1 | $21 |
| Dexcom, Inc. | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Medtronic | 1 | $17 |
| Almatica Pharma LLC | 1 | $17 |
| Smith+Nephew | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Otezla$127
- FreeStyle Libre$104
How this compares
$3,125 in reported general payments places this provider in the 95th percentile of 34 addiction medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 45 | $52,940 |
| EliquisApixaban | 47 | $24,857 |
| BelbucaBuprenorphine Hcl | 12 | $11,510 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $8,066 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 19 | $5,880 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $1,656 |
| Celecoxib | 26 | $919 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 33 | $900 |
| Gabapentin | 41 | $581 |
| Atorvastatin Calcium | 99 | $575 |
| Tamsulosin Hcl | 50 | $570 |
| Rosuvastatin Calcium | 19 | $502 |
| Pregabalin | 26 | $501 |
| Metoprolol Succinate | 27 | $498 |
| Metformin Hcl | 108 | $470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $365 | $52,94045 claims |
| PfizerEliquis | $63 | $24,85747 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 34 addiction medicine providers in Maryland.
Other addiction medicine in Rockville
- Hassaan YousufiRockville$349
- Stanislav MalovRockville$110
- Mary Jo CannonHagerstown$791
- Carolyn ThangawngBaltimore$728
- Drew FullerGlen Burnie$612
- Sughanda KhannaOcean City$598
- Akinlawon AyeniLargo$596
- Gregory BurnettBaltimore$491
- Colleen CeremugaColumbia$426
- Paul KulpinskiBaltimore$425
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.